381 related articles for article (PubMed ID: 27039911)
1. [Recommendations on the use of rituximab for ANCA-associated vasculitis].
Gause AM; Rubbert-Roth A;
Z Rheumatol; 2014 Apr; 73(3):287-9. PubMed ID: 27039911
[TBL] [Abstract][Full Text] [Related]
2. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
5. Targeted immunotherapy strategies in ANCA-associated vasculitis.
Puéchal X
Joint Bone Spine; 2019 May; 86(3):321-326. PubMed ID: 30201478
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
7. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
[TBL] [Abstract][Full Text] [Related]
8. Vasculitis for the internist: focus on ANCA-associated vasculitis.
Chaigne B; Guillevin L
Intern Emerg Med; 2017 Aug; 12(5):577-585. PubMed ID: 28623488
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial.
Charles P; Perrodeau É; Samson M; Bonnotte B; Néel A; Agard C; Huart A; Karras A; Lifermann F; Godmer P; Cohen P; Hanrotel-Saliou C; Martin-Silva N; Pugnet G; Maurier F; Sibilia J; Carron PL; Gobert P; Meaux-Ruault N; Le Gallou T; Vinzio S; Viallard JF; Hachulla E; Vinter C; Puéchal X; Terrier B; Ravaud P; Mouthon L; Guillevin L;
Ann Intern Med; 2020 Aug; 173(3):179-187. PubMed ID: 32479166
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in ANCA-Associated Vasculitis.
Hassan RI; Gaffo AL
Curr Rheumatol Rep; 2017 Feb; 19(2):6. PubMed ID: 28155022
[TBL] [Abstract][Full Text] [Related]
11. [De-escalation of therapy in ANCA-associated vasculitides].
Schinke S; Riemekasten G; Lamprecht P
Z Rheumatol; 2017 Feb; 76(1):15-20. PubMed ID: 27933390
[TBL] [Abstract][Full Text] [Related]
12. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.
Cartin-Ceba R; Fervenza FC; Specks U
Curr Opin Rheumatol; 2012 Jan; 24(1):15-23. PubMed ID: 22089095
[TBL] [Abstract][Full Text] [Related]
13. Late-onset neutropenia after rituximab in ANCA-associated vasculitis.
Knight A; Sundström Y; Börjesson O; Bruchfeld A; Malmström V; Gunnarsson I
Scand J Rheumatol; 2016 Oct; 45(5):404-7. PubMed ID: 26948245
[TBL] [Abstract][Full Text] [Related]
14. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
Hellmich B; Sanchez-Alamo B; Schirmer JH; Berti A; Blockmans D; Cid MC; Holle JU; Hollinger N; Karadag O; Kronbichler A; Little MA; Luqmani RA; Mahr A; Merkel PA; Mohammad AJ; Monti S; Mukhtyar CB; Musial J; Price-Kuehne F; Segelmark M; Teng YKO; Terrier B; Tomasson G; Vaglio A; Vassilopoulos D; Verhoeven P; Jayne D
Ann Rheum Dis; 2024 Jan; 83(1):30-47. PubMed ID: 36927642
[TBL] [Abstract][Full Text] [Related]
15. [ANCA-associated vasculitis].
Holle JU
Internist (Berl); 2015 Jan; 56(1):41-50; quiz 51-2. PubMed ID: 25502657
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
[TBL] [Abstract][Full Text] [Related]
17. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
Charles P; Néel A; Tieulié N; Hot A; Pugnet G; Decaux O; Marie I; Khellaf M; Kahn JE; Karras A; Ziza JM; Deligny C; Tchérakian C; Guillevin L;
Rheumatology (Oxford); 2014 Mar; 53(3):532-9. PubMed ID: 24282319
[TBL] [Abstract][Full Text] [Related]
19. Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study.
Saito A; Takeuchi Y; Kagaya S; Ojima Y; Fukami H; Sato H; Matsuda K; Nagasawa T
Tohoku J Exp Med; 2017 May; 242(1):53-62. PubMed ID: 28539536
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis.
Nagafuchi H; Atsumi T; Hatta K; Muso E; Takeno M; Yamada H; Ozaki S
Mod Rheumatol; 2015 Jul; 25(4):603-8. PubMed ID: 25496405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
